Subjective perception versus objective outcome after intravitreal ranibizumab for exudative AMD

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 250, Issue 2, 2012, Pages 201-209

  Koch, Konrad R ^a   Muether, Philipp S ^a   Hermann, Manuel M ^a   Hoerster, Robert ^a   Kirchhof, Bernd ^a   Fauser, Sascha ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Best corrected visual acuity; Exudative AMD; Ranibizumab treatment; Subjective perception

Indexed keywords

RANIBIZUMAB;

AGED; ARTICLE; CASE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PRIORITY JOURNAL; PROSPECTIVE STUDY; READING; RETINA MACULA AGE RELATED DEGENERATION; SCORING SYSTEM; SELF REPORT; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; VISUAL ACUITY; VISUAL THRESHOLD;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; EXUDATES AND TRANSUDATES; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; PROSPECTIVE STUDIES; READING; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84857368692     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-011-1792-8     Document Type: Article

References (33)

1. Bressler NM, Bressler SB, Congdon NG, Ferris FLR, Friedman DS, Klein R, Lindblad AS, Milton RC, Seddon JM (2003) Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol 121:1621-1624 (Pubitemid 37392370)
2. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419-1431 (Pubitemid 44511557)
3. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432-1444 (Pubitemid 44511558)
4. Klein R, Klein BE, Lee KE (1996) Changes in visual acuity in a population. The Beaver Dam Eye Study. Ophthalmology 103:1169-1178 (Pubitemid 26282496)
5. Roy MS, Skurnick J (2007) Six-year incidence of visual loss in African Americans with type 1 diabetes mellitus: the New Jersey 725. Arch Ophthalmol 125:1061-1067 (Pubitemid 47258035)
6. Schumacher M, Schmidt D, Jurklies B, Gall C, Wanke I, Schmoor C, Maier-Lenz H, Solymosi L, Brueckmann H, Neubauer AS, Wolf A, Feltgen N (2010) Central retinal artery occlusion: local intra-arterial fibrinolysis versus conservative treatment, a multicenter randomized trial. Ophthalmology 117:1367-1375, e1
7. Radner W, Willinger U, Obermayer W, Mudrich C, Velikay-Parel M, Eisenwort B (1998) A new reading chart for simultaneous determination of reading vision and reading speed. Klin Monbl Augenheilkd 213:174-181 (Pubitemid 28460072)
8. Stifter E, Konig F, Lang T, Bauer P, Richter-Muksch S, Velikay- Parel M, Radner W (2004) Reliability of a standardized reading chart system: variance component analysis, test-retest and interchart reliability. Graefes Arch Clin Exp Ophthalmol 242:31-39 (Pubitemid 38208282)
9. Gall C, Wagenbreth C, Sgorzaly S, Franke GH, Sabel BA (2010) Parafoveal vision impairments and their influence on reading performance and self-evaluated reading abilities. Graefes Arch Clin Exp Ophthalmol 248:863-875
10. Radner W, Obermayer W, Richter-Mueksch S, Willinger U, Velikay-Parel M, Eisenwort B (2002) The validity and reliability of short German sentences for measuring reading speed. Graefes Arch Clin Exp Ophthalmol 240:461-467 (Pubitemid 36097067)
11. Burggraaff MC, van Nispen RM, Hoek S, Knol DL, van Rens GH (2010) Feasibility of the Radner Reading Charts in low-vision patients. Graefes Arch Clin Exp Ophthalmol 248:1631-1637
12. Maaijwee K, Mulder P, Radner W, Van Meurs JC (2008) Reliability testing of the Dutch version of the Radner Reading Charts. Optom Vis Sci 85:353-358 (Pubitemid 351643373)
13. Joeres S, Tsong JW, Updike PG, Collins AT, Dustin L, Walsh AC, Romano PW, Sadda SR (2007) Reproducibility of quantitative optical coherence tomography subanalysis in neovascular agerelated macular degeneration. Invest Ophthalmol Vis Sci 48:4300-4307 (Pubitemid 351261062)
14. Singh RP, Fu EX, Smith SD, Williams DR, Kaiser PK (2009) Predictive factors of visual and anatomical outcome after intravitreal bevacizumab treatment of neovascular age-related macular degeneration: an optical coherence tomography study. Br J Ophthalmol 93:1353-1358
15. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ (2011) Ranibizumab and bevacizumab for neovascular agerelated macular degeneration. N Engl J Med 364:1897-1908
16. Hazel CA, Petre KL, Armstrong RA, Benson MT, Frost NA (2000) Visual function and subjective quality of life compared in subjects with acquired macular disease. Invest Ophthalmol Vis Sci 41:1309-1315 (Pubitemid 30261852)
17. McClure ME, Hart PM, Jackson AJ, StevensonMR, Chakravarthy U (2000) Macular degeneration: do conventional measurements of impaired visual function equate with visual disability? Br J Ophthalmol 84:244-250 (Pubitemid 30251677)
18. Richter-Mueksch S, Stur M, Stifter E, Radner W (2006) Differences in reading performance of patients with Drusen maculopathy and subretinal fibrosis after CNV. Graefes Arch Clin Exp Ophthalmol 244:154-162
19. Ergun E, Maar N, Radner W, Barbazetto I, Schmidt-Erfurth U, Stur M (2003) Scotoma size and reading speed in patients with subfoveal occult choroidal neovascularization in age-related macular degeneration. Ophthalmology 110:65-69 (Pubitemid 36068728)
20. Stifter E, Weghaupt H, Benesch T, Thaler A, Radner W (2005) Discriminative power of reading tests to differentiate visual impairment caused by cataract and age-related macular degeneration. J Cataract Refract Surg 31:2111-2119 (Pubitemid 43075377)
21. Frennesson C, Nilsson UL, Peebo BB, Nilsson SE (2010) Significant improvements in near vision, reading speed, central visual field and related quality of life after ranibizumab treatment of wet age-related macular degeneration. Acta Ophthalmo 88:420-425
22. Kaiser PK, Blodi BA, Shapiro H, Acharya NR (2007) Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 114:1868-1875
23. Keane PA, Liakopoulos S, Ongchin SC, Heussen FM, Msutta S, Chang KT, Walsh AC, Sadda SR (2008) Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 49:3115-3120
24. Kiss CG, Geitzenauer W, Simader C, Gregori G, Schmidt-Erfurth U (2009) Evaluation of ranibizumab-induced changes in high-resolution optical coherence tomographic retinal morphology and their impact on visual function. Invest Ophthalmol Vis Sci 50:2376-2383
25. Moutray T, Alarbi M, Mahon G, Stevenson M, Chakravarthy U (2008) Relationships between clinical measures of visual function, fluorescein angiographic and optical coherence tomography features in patients with subfoveal choroidal neovascularisation. Br J Ophthalmol 92:361-364 (Pubitemid 351363531)
26. Keane PA, Liakopoulos S, Chang KT, Wang M, Dustin L, Walsh AC, Sadda SR (2008) Relationship between optical coherence tomography retinal parameters and visual acuity in neovascular age-related macular degeneration. Ophthalmology 115:2206-2214
27. Ach T, Dawczynski J, Konigsdorffer E, Augsten R, Strobel J (2007) Subjective sensations after intravitreal injection of bevacizumab. Klin Monbl Augenheilkd 224:180-184 (Pubitemid 46739635)
28. Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J (2009) Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Arch Ophthalmol 127:13-21
29. Suner IJ, Kokame GT, Yu E,Ward J, Dolan C, Bressler NM (2009) Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials. Invest Ophthalmol Vis Sci 50:3629-3635
30. Bressler NM, Chang TS, Suner IJ, Fine JT, Dolan CM, Ward J, Ianchulev T (2010) Vision-related function after ranibizumab treatment by better-or worse-seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology 117:747-756, e4
31. Blackhurst DW, Maguire MG (1989) Reproducibility of refraction and visual acuity measurement under a standard protocol. The Macular Photocoagulation Study Group. Retina 9:163-169 (Pubitemid 19262177)
32. Beck RW, Moke PS, Turpin AH, Ferris FLR, SanGiovanni JP, Johnson CA, Birch EE, Chandler DL, Cox TA, Blair RC, Kraker RT (2003) A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol. Am J Ophthalmol 135:194-205 (Pubitemid 36151797)
33. Koch KR, Muether PS, Hermann MM, Hoerster R, Kirchhof B, Fauser S (2011) Subjective perception and objective parameters of visual function after intravitreal ranibizumab treatment. ARVO Meet Abstr 52:1662